Moreover, a previous clinical trial has reported that oral proteasome inhibitor ixazomib could downregulate proteasome gene PSMB9 in patients with indolent B-cell non-Hodgkin lymphoma and help to generate anti-S antibodies to SARS-CoV-2 vaccination, indicating the potential relation between PSMB9 expression and COVID-19 infection [42]. This evidence concerns the gene PSMB9 and B-cell non-Hodgkin lymphoma.